Tonttilla 2016.
Study characteristics | |||
Patient sampling | Aim of the study: to compare (TRUS)‐fusion mpMRI‐TBx with routine SBx for overall and clinically significant PCa detection among men with suspected PCa based on PSA values Type of study: prospective RCT, with randomisation 1:1 to the mpMRI or control group. Participants in the mpMRI group underwent pre‐Bx mpMRI followed by SBx and MRI‐TBx; the control group underwent SBx alone. For our current analysis only the mpMRI group is used. Selection: consecutive Enrolled/eligible: 53/65 (of the mpMRI group; 12 participants were excluded because of PSA normalisation, Bx protocol violation or MRI could not be performed) Inclusion period: April 2011‐December 2014 |
||
Patient characteristics and setting | Inclusion criteria:
Exclusion criteria:
Setting: Oulu, Finland, University hospital Age: median 63 years (IQR 60‐66) PSA: median 6.1 ng/mL (IQR 4.2‐9.9) Prostate volume: median 27.8 mL (IQR 23.5‐36.6) |
||
Index tests | Index test 1: MRI‐pathway: a 3 Tesla MRI (Skyra, Siemens) was used. An in‐house MRI score on a 1‐4‐point scale was used:
With score ≥ 3 considered a positive MRI and threshold for MRI‐TBx. MRI was reported before the Bx procedure. Cognitive‐fusion transrectal MRI‐TBx were performed independent from the SBx. Index test 2: standard transrectal 12‐core SBx were performed with blinding for the MRI results and before the performance of the MRI‐TBx |
||
Target condition and reference standard(s) | No reference standard is used in this agreement analyses study (MRI‐pathway vs SBx), therefore the reference standard domain is not applicable and disregarded. | ||
Flow and timing | All participants underwent same tests. Participants with normalised PSA, Bx protocol violation or in which MRI could not be performed were excluded from analysis (n = 12). | ||
Comparative | |||
Notes | Study authors provided additional data. | ||
Methodological quality | |||
Item | Authors' judgement | Risk of bias | Applicability concerns |
DOMAIN 1: Patient Selection | |||
Was a consecutive or random sample of patients enrolled? | Yes | ||
Did the study avoid inappropriate exclusions? | No | ||
High | Low | ||
DOMAIN 2: Index Test SBx | |||
Was the MRI assessed without knowledge of the results of the (reference or other index) biopsies? | |||
Were the MRI‐TBx performed independent of the (reference or other index) biopsies? | |||
Was the performance of the SBx not influenced by the performance of the (reference or other index) biopsies? | Yes | ||
Low | Low | ||
DOMAIN 2: Index Test MRI‐pathway | |||
Was the MRI assessed without knowledge of the results of the (reference or other index) biopsies? | Yes | ||
Were the MRI‐TBx performed independent of the (reference or other index) biopsies? | Yes | ||
Was the performance of the SBx not influenced by the performance of the (reference or other index) biopsies? | |||
Low | High | ||
DOMAIN 3: Reference Standard | |||
Is the reference standards likely to correctly classify the target condition? | Yes | ||
Was the reference standard performed independent from the index test? | Yes | ||
Low | Low | ||
DOMAIN 4: Flow and Timing | |||
Did all patients receive the same reference standard? | Yes | ||
Were all enrolled patients included in the analysis, or were exclusions explained and not leading to a relevant bias? | No | ||
High |